A novel carbon-fibre adjustable reusable accessory (CARA) for supine breast positioning to reduce toxicity in breast adjuvant radiotherapy: a study protocol for a multicentre phase III randomized controlled trial

• Published in: BMC cancer 2022-06, Vol.22 (1), p.1-673, Article 673
• Main Authors: Duzenli, Cheryl, Chan, Elisa K, Bergman, Alanah M, Grahame, Sheri, Singer, Joel, Burns, Levi, Olson, Robert A
• Format: Article
• Language: English
• Subjects: Adjuvant radiotherapy; Body mass index; Body size; Breast; Breast cancer; Breasts; Cancer therapies; Carbon; Care and treatment; Clinical trials; Evaluation; Heart; Infra-mammary fold; Medical equipment; Methods; Moist desquamation; Patient outcomes; Patients; Physiological apparatus; Planning; Population studies; Quality of life; Radiation therapy; Radiotherapy; Reproducibility; Skin; Skin toxicity; Study Protocol; Supine positioning; Toxicity
• ISSN: 1471-2407; 1471-2407
• DOI: 10.1186/s12885-022-09759-y

Background A novel device for supine positioning in breast radiotherapy for patients with large or pendulous breasts has been developed and tested in phase II studies. This trial is designed to assess the efficacy of the device to reduce skin toxicity and unwanted normal tissue dose in comparison to the current clinical standard for supine breast support during breast radiotherapy. Methods Patients at high risk for moist desquamation, having infra-mammary fold or lateral ptosis, will be randomized into two arms. Patients in the control arm will receive breast radiotherapy with supine positioning using current standard of care. Patients in the experimental arm will be positioned supine with the novel device. The primary endpoint is the incidence of moist desquamation in the infra-mammary fold. We hypothesize a 20% reduction (from 50 to 30%) in the rate of moist desquamation in the study arm versus the control arm. For 80% power, two-tailed [alpha] = 0.05 and 10% loss to follow up, 110 patients will be assigned to each arm. The proportion of patients experiencing moist desquamation in the two arms will be compared using logistic regression adjusting for brassiere cup size, skin fold size, body mass index, smoking status, and dose fractionation schedule. An unadjusted comparison will also be made using the chi-square test, or Fisher's exact test, if appropriate. Secondary endpoints include dose-volume statistics for the lung and heart, skin dose and clinical parameters including setup time, reproducibility, and staff experience with setup procedures. Patient-reported pain, skin condition interference with sleep and daily activities, and comfort during treatment are also secondary endpoints. Discussion Based on results from earlier phase II studies, it is expected that the device-enabled elimination of infra-mammary fold should reduce toxicity and improve quality of life for this patient population. Earlier studies showed reduction in dose to organs at risk including lung and heart, indicating potential for other long-term benefits for patients using the device. This study is limited to acute skin toxicity, patient-reported outcomes, and clinical factors to inform integration of the device into standard breast radiotherapy procedures. Trial registration Clinicaltrials.gov identifier: NCT04257396. Registered February 6 2020. Keywords: Breast cancer, Supine positioning, Adjuvant radiotherapy, Skin toxicity, Moist desquamation, Infra-mammary fold, Breast support,